Krs-2 Activators
Krs-2 activators constitute a class of chemicals carefully chosen for their potential to modulate the activity of Krs-2, a protein intimately involved in the mitogen-activated protein kinase (MAPK) pathway. While direct activators may not be explicitly identified, these chemicals exert their effects through indirect mechanisms, primarily by targeting key components of the MAPK pathway, such as Raf and MEK. Sorafenib, for instance, is a multikinase inhibitor that inhibits Raf kinases, subsequently disrupting the MAPK pathway and indirectly inhibiting the activation of Krs-2. Trametinib and U0126, selective MEK inhibitors, interfere with the phosphorylation cascade within the MAPK pathway, specifically targeting MEK. By doing so, these inhibitors disrupt the downstream events leading to the activation of Krs-2. These indirect modulators showcase the interconnectedness of signaling pathways and how perturbation at one point can influence the entire cascade, ultimately impacting the regulatory role of Krs-2 in cellular processes related to growth and survival.
Furthermore, the chemical class includes inhibitors like BI-D1870, targeting p90 ribosomal S6 kinase (RSK), a downstream effector of the MAPK pathway. Inhibition of RSK indirectly affects the activation of Krs-2, revealing the intricate network of signaling events governing Krs-2 activity. The comprehensive list of Krs-2 activators underscores the importance of the MAPK pathway in regulating Krs-2 and provides valuable insights into potential pharmacological interventions for studying its intricate regulatory mechanisms.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multikinase inhibitor that targets Raf kinases among other pathways. As a Raf inhibitor, sorafenib modulates the MAPK pathway by preventing the activation of Krs-2, a downstream target of Raf kinases. By blocking this pathway, sorafenib indirectly inhibits the activation of Krs-2 and downstream signaling cascades associated with cell proliferation and survival. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a selective MEK inhibitor that impacts the MAPK pathway. By inhibiting MEK, trametinib disrupts the downstream signaling events, including the activation of Krs-2. This inhibition of the MAPK pathway, known for its role in cellular growth and differentiation, indirectly affects the activation of Krs-2 and its involvement in critical cellular processes. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Selumetinib, a selective MEK1/2 inhibitor, hinders the activation of the MAPK pathway. By specifically targeting MEK1/2, selumetinib disrupts the phosphorylation events leading to the activation of Krs-2. The inhibition of the MAPK pathway by selumetinib can indirectly influence the activation status of Krs-2, contributing to its regulatory role in cellular processes such as proliferation and differentiation. | ||||||
BI-D1870 | 501437-28-1 | sc-397022 sc-397022A | 1 mg 5 mg | $92.00 $260.00 | 12 | |
BI-D1870 is a selective inhibitor of p90 ribosomal S6 kinase (RSK), which is downstream of the MAPK pathway. By inhibiting RSK, BI-D1870 indirectly affects the activation of Krs-2, which is regulated by the MAPK pathway. The inhibition of RSK by BI-D1870 disrupts the downstream signaling events, potentially altering the activation status of Krs-2 and its involvement in cellular processes related to cell growth and survival. | ||||||
RAF265 | 927880-90-8 | sc-364599 | 5 mg | $191.00 | ||
RAF265 is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), a key component of the MAPK pathway. By targeting MEK, CHIR-265 disrupts the phosphorylation cascade that leads to the activation of Krs-2. | ||||||
ERK Inhibitor II, FR180204 | 865362-74-9 | sc-203945 sc-203945A sc-203945B sc-203945C | 1 mg 5 mg 10 mg 50 mg | $110.00 $165.00 $239.00 $942.00 | 45 | |
FR180204 is a selective ERK inhibitor that acts on the MAPK pathway. By inhibiting ERK, FR180204 disrupts the downstream signaling events leading to the activation of Krs-2. The inhibition of the MAPK pathway by FR180204 can indirectly influence the activation status of Krs-2, contributing to its regulatory role in cellular processes such as proliferation and differentiation. | ||||||
AS703026 | 1236699-92-5 | sc-364412 sc-364412A | 5 mg 10 mg | $80.00 $130.00 | ||
AS703026 is a selective MEK1/2 inhibitor that impacts the MAPK pathway. By inhibiting MEK1/2, AS703026 disrupts the phosphorylation events leading to the activation of Krs-2. The inhibition of the MAPK pathway by AS703026 can indirectly influence the activation of Krs-2, contributing to its regulatory role in cellular processes such as proliferation and differentiation. | ||||||
BAY 869766 | 923032-37-5 | sc-364427 sc-364427A | 5 mg 10 mg | $245.00 $428.00 | 1 | |
Refametinib, also known as BAY 86-9766, is a potent and selective MEK inhibitor. By targeting MEK, Refametinib disrupts the MAPK pathway, inhibiting the phosphorylation and activation of Krs-2. This interruption of the MAPK pathway can indirectly modulate the activation of Krs-2, influencing downstream cellular processes associated with cell proliferation, differentiation, and survival. | ||||||